Several prognostic indicators demonstrated significant correlations with enhanced PFS and extended OS, including patients aged >50 years, PD-L1 expression levels (CPS ≥ 1 compared to <1 and CPS ≥ 10 versus <1), elevated tumor mutational burden, and presence of PIK3CA genetic alterations (62). This evidence concerns the gene CD274 and neoplasm.